RT Journal Article
SR Electronic
T1 Prolonged SARS-CoV-2 infection in patients with lymphoid malignancies
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.08.25.21262417
DO 10.1101/2021.08.25.21262417
A1 Lee, Christina Y.
A1 Shah, Monika K.
A1 Hoyos, David
A1 Solovyov, Alexander
A1 Douglas, Melanie
A1 Taur, Ying
A1 Maslak, Peter G.
A1 Babady, N. Esther
A1 Greenbaum, Benjamin
A1 Kamboj, Mini
A1 Vardhana, Santosha A.
YR 2021
UL http://medrxiv.org/content/early/2021/08/29/2021.08.25.21262417.abstract
AB Coronavirus disease 2019 (COVID-19) infection results in high mortality rates in patients with hematologic malignancies. Persistent and/or recurrent COVID-19 has not yet been demonstrated in this population. We identified patients with B-cell lymphomas as having a particularly high risk for persistent SARS-CoV-2 positivity. Subsequent analysis of patients with lymphoid malignancies and COVID-19 identified discrete risk factors for severity of primary infection as compared to disease chronicity. Active therapy and diminished T-cell counts were key drivers of acute mortality in lymphoma patients with COVID-19 infection. Conversely, B-cell depleting therapy was the primary driver of re-hospitalization for COVID-19. In patients with persistent SARS-CoV-2 positivity, we observed high levels of viral entropy consistent with intrahost viral evolution, particularly in patients with impaired CD8+ T-cell immunity. These results suggest that persistent COVID-19 infection is likely to remain a risk in patients with impaired adaptive immunity and that additional therapeutic strategies are needed to enable viral clearance in this high-risk population.Statement of Significance We establish persistent symptomatic COVID-19 infection as a novel clinical syndrome in patients with lymphoid malignancies and identify B-cell depletion as the key immunologic driver of persistent infection. Furthermore, we demonstrate ongoing intrahost viral evolution in patients with persistent COVID-19 infection, particularly in patients with impaired CD8+ T-cell immunity.Competing Interest StatementC.Y.L, M.K., M.K.S: No disclosuresN.E.B has received research funding from GenMark and Copan, is on the advisory board of Arc Bio and has served on ad-hoc scientific advisory boards for Roche and Karius.B.G. has received honoraria for speaking engagements from Merck, Bristol Meyers Squibb, and Chugai Pharmaceuticals; has received research funding from Bristol Meyers Squibb and Merck; and has been a compensated consultant for Darwin Health, Merck, PMV Pharma and Rome Therapeutics of which he is a co founder.S.A.V. is on the advisory board for Immunai and has received consulting fees from ADC Therapeutics.Funding StatementP30 CA 008748 from NIH/NCI Cancer Center Support Grant Philanthropic support from Jack and Dorothy Byrne Foundation (to M.K. and N.E.B) Pershing Square Sohn Cancer Research Foundation and Conrad Hilton Foundation (to S.A.V.)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This research was performed under the consent of MSKCC's institutional review board (IRB #20-184)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesSharing of de-identified clinical data, upon request, will be considered by MSKCC's institutional review board (IRB).